scholarly journals PIN60 Cost-Effectiveness of Quadrivalent Influenza Vaccine High Dose Versus Adjuvanted Standard Dose Trivalent Influenza Vaccine in England

2020 ◽  
Vol 23 ◽  
pp. S555
Author(s):  
I. Gibbons ◽  
C. Davidson ◽  
J. Clark-Wright ◽  
C. Miller ◽  
S. Carroll ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccine ◽  
Standard Dose ◽  
High Dose ◽  
Trivalent Influenza Vaccine ◽  
Quadrivalent Influenza Vaccine

scholarly journals Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

2021 ◽  
Vol 8 ◽  
pp. 105-113
Author(s):  
Filippo Rumi ◽  
Michele Basile ◽  
Americo Cicchetti
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccine ◽  
Elderly Population ◽  
Impact Analysis ◽  
Budget Impact ◽  
Standard Dose ◽  
Public Health Problem ◽  
High Dose ◽  
Health Technologies ◽  
Quadrivalent Influenza Vaccine

Introduction. Influenza is a widespread acute respiratory disease and represents a serious Public Health problem, both from the NHS and society perspectives. The High Dose quadrivalent influenza vaccine (QIV HD) is a flu vaccine containing 4 times the antigens of a Standard Dose vaccine, resulting in demonstrated superior protection in the population aged 65 years and over. Methods. The analysis has been conducted from the perspective of the NHS. The CEA focuses on the comparison between QIV HD and the QIV SD vaccine. The BIM aims to estimate the potential economic impact for the National Health Service (NHS) resulting from the use of QIV HD in clinical practice in subjects aged 65 or over, when considering its introduction in combination with currently used vaccines, QIV SD and adjuvanted TIV. Results. In a scenario which considers hospitalizations possibly related to influenza, so including cardio-respiratory events, a dominant cost-effectiveness profile emerges in the comparison with QIV SD. In terms of budget impact, overall savings obtained by comparing the two scenarios regarding hospitalizations are equal to 92,766,429 € over the three years’ time horizon considered in the analysis. Conclusions. Nowadays, also considering the state of emergency due to the spread of the SARS-CoV-2 virus, it is crucial to implement innovative health technologies that improve the efficiency and sustainability of the health system. Also, it is essential to protect the elderly population, helping to avoid overload and healthcare systems disruption due to the many COVID-19 hospitalizations.

High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009–2010 season

Vaccine ◽  
2013 ◽  
Vol 31 (6) ◽  
pp. 861-866 ◽  
Author(s):  
Carlos A. DiazGranados ◽  
Andrew J. Dunning ◽  
Emilia Jordanov ◽  
Victoria Landolfi ◽  
Martine Denis ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Standard Dose ◽  
High Dose ◽  
Elderly Adults ◽  
Relative Efficacy ◽  
Trivalent Influenza Vaccine ◽  
Dose Vaccine

scholarly journals Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors

Vaccine ◽  
2015 ◽  
Vol 33 (5) ◽  
pp. 734-741 ◽  
Author(s):  
Ayman Chit ◽  
Julie Roiz ◽  
Benjamin Briquet ◽  
David P. Greenberg
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccine ◽  
High Dose ◽  
Expected Cost ◽  
Trivalent Influenza Vaccine

scholarly journals Comparison of Side Effects of the 2015–2016 High-Dose, Inactivated, Trivalent Influenza Vaccine and Standard Dose, Inactivated, Trivalent Influenza Vaccine in Adults ≥65 Years

2017 ◽  
Vol 4 (1) ◽  
Author(s):  
Anjum S. Kaka ◽  
Gregory A. Filice ◽  
Sharon Myllenbeck ◽  
Kristin L. Nichol
Keyword(s):  
Side Effects ◽  
Influenza Vaccine ◽  
Side Effect ◽  
Standard Dose ◽  
Severe Side Effect ◽  
High Dose ◽  
Trivalent Influenza Vaccine ◽  
Significant Difference ◽  
Research Assistants ◽  
Better Than

Abstract Background High-dose, inactivated, trivalent influenza vaccine (HD) is associated with higher rates of side effects than standard dose (SD) vaccine, which may represent a barrier to use. Methods We surveyed subjects ≥65 years who received either HD or SD vaccine at the Minneapolis Veteran Affairs Health Care System clinics on October 27, 28, or 29, 2015. Research assistants conducted a 17-item telephone survey of influenza vaccine recipients to inquire about self-reported health and symptoms experienced the week after vaccination. Results A total of 547 HD recipients and 541 SD recipients responded to the survey. The 2 groups were similar at baseline with respect to age, gender, and presence of high-risk medical conditions. At least ≥95% of individuals in both HD and SD groups reported that their overall health was the same or better than usual during the week after vaccination. Thirty-seven percent of HD recipients and 22% of SD recipients reported a local or systemic side effect (P < .001), most of which were mild to moderate. Only 7 of 547 (1.3%) HD recipients and 3 of 541 (0.6%) SD recipients reported a severe side effect (P = .34). There was no significant difference in healthcare visits between the groups. Conclusions Side effects were more common among subjects ≥65 years who received HD influenza vaccine compared with SD vaccine. These side effects were well tolerated and were not associated with impairment of general health status. These findings should reassure patients and their providers of the safety and tolerability of the HD influenza vaccine.

scholarly journals High-dose trivalent influenza vaccine. Efficacy and effectiveness

2020 ◽  
Vol 33 (4) ◽  
pp. 226-239
Author(s):  
Ángel Gil de Miguel ◽  
Esther Redondo Marguello ◽  
Javier Díez Domingo ◽  
Raúl Ortiz de Lejarazu ◽  
Federico Martinón Torres ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Influenza Virus ◽  
Virus Infection ◽  
Influenza Vaccine ◽  
Older People ◽  
Standard Dose ◽  
Influenza Virus Infection ◽  
High Dose ◽  
Trivalent Influenza Vaccine ◽  
Dose Vaccine

Seasonal influenza is a major public health problem, particularly in older people. Influenza vaccine is the most effective way to prevent influenza virus infection and its complications, but due to immunosenescence, older people do not respond efficiently to immunization. In 2009, a high-dose trivalent influenza vaccine (IIV3-HD), containing four times more antigen than the standard-dose vaccine, was approved in the United States for the immunization of people aged 65 years and over. Numerous clinical trials, carried out at different seasons and using different methodologies, have shown that the IIV3-HD vaccine is, as well as safe, more immunogenic and more effective than the standard-dose vaccine in preventing influenza virus infection and its complications in older people. This paper reviews the available evidence on the efficacy and effectiveness of the IIV3-HD influenza vaccine in the elderly, with information from randomized clinical trials, as well as observational studies of real-world clinical practice and in systematic reviews/meta-analyses.

Sign in / Sign up

Export Citation Format

Share Document